no credit card required  No credit card. No commitment.
 5000 plus G2 reviews  5000+ G2 reviews
Company logo

CellCarta formerly HistoGeneX

CellCarta formerly HistoGeneX


CellCarta formerly HistoGeneX's financial review

CellCarta formerly HistoGeneX's Revenue (Yearly)

35M

Employees

110


CellCarta formerly HistoGeneX information

At HistoGeneX, we take pride in bridging technologies, expertise, and experience. Connect with us on Twitter @HistoGeneX or visit HistoGeneX Laboratories on Youtube.HistoGeneX Laboratories is a privately held service provider of biomarker technologies for translational and clinical research and is a CAP, CLIA and BELAC-accredited laboratory. With facilities located in Antwerp, Belgium and Chicago,...
At HistoGeneX, we take pride in bridging technologies, expertise, and experience. Connect with us on Twitter @HistoGeneX or visit HistoGeneX Laboratories on Youtube.HistoGeneX Laboratories is a privately held service provider of biomarker technologies for translational and clinical research and is a CAP, CLIA and BELAC-accredited laboratory. With facilities located in Antwerp, Belgium and Chicago, Illinois, and Jining, China, HistoGeneX provides a networked footprint for global clinical trials. Our services and products stem from a pathology and patient care perspective. We are experts at handling all human biological specimens and deploy the relevant technologies to extract the valuable information contained within for research and diagnostic applications.We provide assay development and testing services to support a wide variety of translational medicine, clinical trials, and in vitro diagnostic applications. Our laboratory combines innovative technologies to interrogate DNA, RNA and proteins to categorize, enumerate and understand cancer. Our leadership comes from various aspects of diagnostic and therapeutic backgrounds. HistoGeneX leads the biomarker immune-oncology field. We have devoted attention to developing innovations in assessing the immune system within the tumor microenvironment. Our key advances include:· A strong portfolio of immuno-oncology related biomarkers.· A large number of immuno-oncology trials across multiple tumor types.· Experience with semi-quantitative and quantitative imaging.· Experience with IVD assays and diagnostic companies.· Self-Investment in immuno-oncology research.

CellCarta formerly HistoGeneX industries

Oncology
Tissue analysis
Molecular techniques
Tumor profiling

CellCarta formerly HistoGeneX's financial review

CellCarta formerly HistoGeneX's Revenue (Yearly)

35M

Employees

110

Prospect on LinkedIn

Find verified emails and direct dial mobile numbers of contacts on LinkedIn, and sync them with your CRM instantly
Download ExtensionRepresents linkedin prospector
Browse Apollo's Directories

Why our clients choose Apollo

“Apollo completely changed the game for us. It allowed us to identify relevant targets that are ready to scale and reach out to them at the exact right time.”
Image of Erik Straub

Erik Straub

Head of Product, Kickfurther

“Using Apollo.io, we've solved the biggest problem for every business, the lead problem. We are now constrained by sales time and no longer lack interested prospects.”
Image of Michael Transon

Michael Transon

CEO, Victorious

Apollo gives you all the company insights you need

Free to get started, easy to add your whole sales team, commit to monthly or annual plans. We make it easy to get started.